Clinical Report: The Test That Could Save Patients' Bladders

Overview

Monitoring tumor-derived DNA in blood and urine can identify patients with muscle-invasive bladder cancer who may avoid bladder removal. A study found that ctDNA and utDNA provide complementary information for predicting cancer recurrence and bladder preservation.

Background

Muscle-invasive bladder cancer (MIBC) is traditionally treated with radical cystectomy, a procedure that significantly alters urinary function. Recent advancements in liquid biopsy techniques, such as ctDNA and utDNA analysis, offer potential for bladder preservation by identifying patients at lower risk of recurrence. Understanding these biomarkers is crucial for optimizing treatment strategies and improving patient quality of life.

Data Highlights

Key Findings

• ctDNA detected before systemic therapy correlates with a higher risk of metastatic disease.
• Patients with undetectable baseline ctDNA have a lower risk of disease progression.
• utDNA is more sensitive than ctDNA for detecting residual disease confined to the bladder.
• Detectable utDNA in patients without visible cancer is linked to shorter bladder-intact survival.
• Integration of liquid biopsy assays into routine management may enhance patient selection for bladder preservation.

Clinical Implications

The findings suggest that incorporating ctDNA and utDNA testing into clinical practice could help identify patients who can safely avoid radical cystectomy. This approach may lead to improved patient outcomes and preserve urinary function for selected individuals.

Conclusion

The study underscores the potential of liquid biopsy assays in managing muscle-invasive bladder cancer, paving the way for future research and clinical applications in bladder preservation strategies.

References

1. Matthew D. Galsky, Proceedings of the National Academy of Sciences, 2026 -- The Test That Could Save Patients' Bladders
2. Matthew R. Zilbelman, The ASCO Post, 2026 -- Combined Tests Could Avoid Unnecessary Cystectomy
3. the asco post — Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
4. The ASCO Post — Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
5. EAU Guidelines on Muscle-Invasive Bladder Cancer 2025
6. Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
7. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer - PubMed